Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 3Sarcoma 1Breast 1

Conditions

Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Mesothelioma, Malignant 1Lung Neoplasms 1Kidney Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 24Nivolumab 7Early Intervention, Educational 7Methods 6durvalumab 5aldesleukin 5Trastuzumab 5Paclitaxel 5Fulvestrant 5Carboplatin 5atezolizumab 4Surveys and Questionnaires 4Patient Navigation 4Docetaxel 4Cyclophosphamide 4Biopsy 4fludarabine 3Mass Screening 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Interleukin-2 3Gene Expression Profiling 3Fluorouracil 3Educational Status 3Bevacizumab 3tremelimumab 2spartalizumab 2sargramostim 2palbociclib 2fludarabine phosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × FANG vaccine × Breast × Clear all
NCT02725489 2021-01-27

Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers

Mary Crowley Medical Research Center

Phase 2 Completed
13 enrolled
BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡